Vesicular stromatitis virus (VSV)

A virus and tumor technology, applied in the direction of viruses, viral peptides, viruses/phages, etc., can solve the problem of not testing the anti-VSV cytotoxic activity
CN1496268AInactive Publication Date: 2004-05-12VIRUSTA BIOLOGICAL
8 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
VIRUSTA BIOLOGICAL
Publication Date
2004-05-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterised by having low levels, or no PKR activity, or as being PKR- / -, STAT1- / - or both PKR- / - and STAT- / -. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the benefit of U.S. Provisional Application ________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ year September 17, the contents of which are incorporated herein by reference.

[0002] The present invention relates to a novel method of cancer treatment. More specifically, the invention relates to viruses that selectively infect and inhibit the growth of tumor cells. Background of the invention

[0003] The use of oncolytic bacteria or compositions of oncolytic bacteria to attack human and animal neoplasms is known. For example, European Patent 546 121, British Patent 1,587,244 and US Patent 3,192,116 disclose the use of non-pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More